These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 15770606)
1. Prevention of peritoneal sclerosis: a new proposal to substitute glucose with carnitine dialysis solution (biocompatibility testing in vitro and in rabbits). Gaggiotti E; Arduini A; Bonomini M; Valentini G; Sacchi G; Sansoni E; Salvo D; Di Paolo N Int J Artif Organs; 2005 Feb; 28(2):177-87. PubMed ID: 15770606 [TBL] [Abstract][Full Text] [Related]
2. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid. Skoufos L; Topley N; Cooker L; Dawnay A; Millar DJ; Holmes CJ; Faict D Kidney Int Suppl; 2003 Dec; (88):S94-9. PubMed ID: 14870882 [TBL] [Abstract][Full Text] [Related]
3. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Ha H; Yu MR; Choi HN; Cha MK; Kang HS; Kim MH; Lee HB Perit Dial Int; 2000; 20 Suppl 5():S10-8. PubMed ID: 11229606 [TBL] [Abstract][Full Text] [Related]
4. Effect of bicarbonate/lactate peritoneal dialysis solutions on human mesothelial cell proliferation ex vivo. Bajo MA; del Peso G; Castro MA; Díaz C; Castro MJ; Gil F; Sánchez-Tomero JA; Selgas R Adv Perit Dial; 2001; 17():37-41. PubMed ID: 11510293 [TBL] [Abstract][Full Text] [Related]
5. A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with l-Carnitine Improves Biocompatibility on Human Mesothelial Cells. Piccapane F; Bonomini M; Castellano G; Gerbino A; Carmosino M; Svelto M; Arduini A; Procino G Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374405 [TBL] [Abstract][Full Text] [Related]
8. Studying the effects of new peritoneal dialysis solutions on the peritoneum. Chan TM; Yung S Perit Dial Int; 2007 Jun; 27 Suppl 2():S87-93. PubMed ID: 17556337 [TBL] [Abstract][Full Text] [Related]
9. L-carnitine is an osmotic agent suitable for peritoneal dialysis. Bonomini M; Pandolfi A; Di Liberato L; Di Silvestre S; Cnops Y; Di Tomo P; D'Arezzo M; Monaco MP; Giardinelli A; Di Pietro N; Devuyst O; Arduini A Kidney Int; 2011 Sep; 80(6):645-54. PubMed ID: 21525850 [TBL] [Abstract][Full Text] [Related]
10. Acute effects of peritoneal dialysis solutions in the mesenteric microcirculation. Frajewicki V; Brod V; Kushnir D; Kohan R; Bitterman H Transl Res; 2009 May; 153(5):249-56. PubMed ID: 19375686 [TBL] [Abstract][Full Text] [Related]
11. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Boulanger E; Wautier MP; Gane P; Mariette C; Devuyst O; Wautier JL Nephrol Dial Transplant; 2004 Sep; 19(9):2208-16. PubMed ID: 15213320 [TBL] [Abstract][Full Text] [Related]
12. [L-carnitine in peritoneal dialysis]. De Vecchi AF; Arduini A; Di Liberato L; Bonomini M G Ital Nefrol; 2011; 28(4):393-400. PubMed ID: 21809308 [TBL] [Abstract][Full Text] [Related]
13. Glucose-based peritoneal dialysis fluids downregulate toll-like receptors and trigger hyporesponsiveness to pathogen-associated molecular patterns in human peritoneal mesothelial cells. Wu J; Yang X; Zhang YF; Wang YN; Liu M; Dong XQ; Fan JJ; Yu XQ Clin Vaccine Immunol; 2010 May; 17(5):757-63. PubMed ID: 20200188 [TBL] [Abstract][Full Text] [Related]
14. Glucose-based PD solution, but not icodextrin-based PD solution, induces plasminogen activator inhibitor-1 and tissue-type plasminogen activator in human peritoneal mesothelial cells via ERK1/2. Katsutani M; Ito T; Masaki T; Kohno N; Yorioka N Ther Apher Dial; 2007 Apr; 11(2):94-100. PubMed ID: 17381529 [TBL] [Abstract][Full Text] [Related]
15. Long-term effects of glycylglycine peritoneal dialysis solution with neutral pH on peritoneum in rats. Wieczorowska-Tobis K; Korybalska K; Polubińska A; Radkowski M; Breborowicz A; Montagne A; Oreopoulos DG Adv Perit Dial; 1997; 13():42-6. PubMed ID: 9360649 [TBL] [Abstract][Full Text] [Related]
16. Recent concepts in the molecular biology of the peritoneal membrane - implications for more biocompatible dialysis solutions. Mortier S; De Vriese AS; Lameire N Blood Purif; 2003; 21(1):14-23. PubMed ID: 12566656 [TBL] [Abstract][Full Text] [Related]
17. Peritoneal dialysis and inflammation. Velloso MS; Otoni A; de Paula Sabino A; de Castro WV; Pinto SW; Marinho MA; Rios DR Clin Chim Acta; 2014 Mar; 430():109-14. PubMed ID: 24333488 [TBL] [Abstract][Full Text] [Related]
18. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis. Higuchi C; Nishimura H; Sanaka T Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191 [TBL] [Abstract][Full Text] [Related]
19. Impacts of icodextrin on integrin-mediated wound healing of peritoneal mesothelial cells. Matsumoto M; Tamura M; Miyamoto T; Furuno Y; Kabashima N; Serino R; Shibata T; Kanegae K; Takeuchi M; Abe H; Okazaki M; Otsuji Y Life Sci; 2012 Jun; 90(23-24):917-23. PubMed ID: 22564410 [TBL] [Abstract][Full Text] [Related]
20. Mesothelial biocompatibility of peritoneal dialysis solutions. Di Paolo N; Garosi G; Traversari L; Di Paolo M Perit Dial Int; 1993; 13 Suppl 2():S109-12. PubMed ID: 8399542 [No Abstract] [Full Text] [Related] [Next] [New Search]